Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000660987
Ethics application status
Approved
Date submitted
28/06/2011
Date registered
29/06/2011
Date last updated
12/11/2018
Date data sharing statement initially provided
12/11/2018
Date results information initially provided
12/11/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Using d-cycloserine to increase the effects of exposure for children's general fears
Scientific title
d-cycloserine vs placebo combined with in-vivo exposure in the reduction of specific fears among children with broad-based anxiety disorders
Secondary ID [1] 262495 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Child anxiety 268182 0
Condition category
Condition code
Mental Health 268311 268311 0 0
Anxiety

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
d-cycloserine - 50 mg oral capsules, taken on 5 weekly occasions, approximately 60 minutes prior to each initial exposure
in-vivo exposure - 5 weekly sessions of approximately 30 minutes with a therapist. Exposure is conducted hierarchically during sessions to main identified fear.
Intervention code [1] 266848 0
Behaviour
Intervention code [2] 266849 0
Treatment: Drugs
Comparator / control treatment
placebo - oral microcellulose capsule taken as above - ie 5 indiviaul doses at weekly sessions approximately 60 minutes prior to initial exposure.
All participants (including those on placebo) receive identical in-vivo exposure.
Control group
Placebo

Outcomes
Primary outcome [1] 269065 0
Anxiety and avoidance of key fear assessed via behavioural avoidance test
Timepoint [1] 269065 0
Pre, Weekly for 5 weeks, post
Secondary outcome [1] 276892 0
General anxiousness assessed via Spence Children's Anxiety Scale
Timepoint [1] 276892 0
Pre, Weekly for 5 weeks, post

Eligibility
Key inclusion criteria
DSM diagnosis of anxiety disorder
Availability of specific fear
Minimum age
7 Years
Maximum age
14 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Psychotic experiences
Suicidal risk
Kidney disease
Liver disease
Epilepsy
Prior allergic reaction to antibiotics

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants are diagnosed and assessed by clinician who is independent of study. All those who meet criteria are invited to participate. Group allocation (active vs placebo) done by random number generator. Allocation and blind is held by hosptial pharmacist who is not involved in study in any other way. Therapist, interviewers, and participants are all blind to condition.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Random number generator.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/09/2011
Actual
15/08/2011
Date of last participant enrolment
Anticipated
Actual
1/12/2012
Date of last data collection
Anticipated
Actual
1/07/2013
Sample size
Target
100
Accrual to date
Final
100
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 267325 0
Government body
Name [1] 267325 0
Australian Research Council
Country [1] 267325 0
Australia
Primary sponsor type
University
Name
Macquarie University
Address
Balaclava Rd
North Ryde.
NSW. 2109
Country
Australia
Secondary sponsor category [1] 266391 0
None
Name [1] 266391 0
Address [1] 266391 0
Country [1] 266391 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 269311 0
Macquarie University Human Research Ethics Committee
Ethics committee address [1] 269311 0
Balaclava Rd.
North Ryde.
NSW. 2109.
Ethics committee country [1] 269311 0
Australia
Date submitted for ethics approval [1] 269311 0
06/07/2011
Approval date [1] 269311 0
01/08/2011
Ethics approval number [1] 269311 0

Summary
Brief summary
The trial aims to test the efficacy of d-cycloserine (DCS) to augment the effects of in-vivo exposure for children's fears. It is hypothesised that anxious children who receive in-vivo exposure for a specific fear will show reductions in that fear and that use of DCS will increase the rate and extent of fear reduction. Children will receive 5 individual sessions of graduated exposure for a key, specific fear and will take either DCS (50 mg) or placebo approx 60 minutes before exposure.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 32803 0
Prof Ronald Rapee
Address 32803 0
Department of Psychology,
Macquarie University
Sydney
NSW 2109 Australia
Country 32803 0
Australia
Phone 32803 0
+61 2 98508032
Fax 32803 0
Email 32803 0
[email protected]
Contact person for public queries
Name 16050 0
Prof Ronald Rapee
Address 16050 0
Department of Psychology,
Macquarie University,
Sydney. NSW. 2109.
Country 16050 0
Australia
Phone 16050 0
61 2 98508032
Fax 16050 0
61 2 98508062
Email 16050 0
[email protected]
Contact person for scientific queries
Name 6978 0
Prof Ronald Rapee
Address 6978 0
Department of Psychology,
Macquarie University,
Sydney. NSW. 2109
Country 6978 0
Australia
Phone 6978 0
61 2 98508032
Fax 6978 0
61 2 98508062
Email 6978 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
This trial finished several years ago and we do not have ethics approval to share the data!


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Plain language summaryNo Use of the partial NMDA receptor agonist d-Cyclose... [More Details]

Documents added automatically
No additional documents have been identified.